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Introduction: Hyperhomocysteinemia has been linked to cardiovascular morbidity and 
mortality by numerous authors. Whether this association is causal or not remains uncertain. The 
aim of the study was to investigate the association of hyperhomocysteinemia with the degree 
of carotid atherosclerosis in stroke patients.
Methods: We studied 97 Greek patients in our stroke unit who were hospitalized as a result 
of ischemic stroke between March 2006 and May 2007. The patients were divided into two 
groups: the ﬁ  rst (52 patients) included stroke patients with serum levels of homocysteine below 
15 µmol/L, but in the second group (45 patients) serum homocysteine exceeded this value. We 
measured carotid intima-media thickness (cIMT) in all patients and correlated it with serum 
homocysteine.
Results: The mean homocysteine concentration was 11.5 µmol/L in the ﬁ  rst group and 
21.5 µmol/L in the second group. Carotid IMT was 1.012 mm in the ﬁ  rst group, and 1.015 mm 
in the second group, an insigniﬁ  cant difference. On the contrary, serum folate concentration 
was 21.3 nmol/L in the ﬁ  rst group compared with 16.7 nmol/L in the second group (p  0.001). 
VitB12 was 401 pmol/L in the ﬁ  rst group and 340 pmol/L in the second group, a statistically 
signiﬁ  cant difference (p  0.001).
Conclusions: Serum levels of homocysteine were not correlated with cIMT in ischemic 
stroke patients. Both folate and vitB12 were decreased in hyperhomocysteinemic ischemic 
stroke patients.
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Introduction
Hyperhomocysteinemia has been linked to cardiovascular morbidity and mortality 
by numerous authors (Matetzky et al 2003). Whether this association is causal or not 
remains uncertain. Homocysteine is a sulfur-containing amino acid which can either 
be remethylated to methionine, or transulphurated to cysteine. In the ﬁ  rst case, folic 
acid and cobalamin (vitB12) are used as coenzymes, whereas in the latter pathway 
pyridoxine (vitB6) is utilized (Finkelstein 2000).
Homocysteine levels below 15 µmol/L are considered normal. Hyperhomocys-
teinemia has been classiﬁ  ed as follows (Kang et al 1992): 15–30 µmol/L, moderate; 
30–100 µmol/L, intermediate; higher than 100 µmol/L, severe.
This study aimed to investigate the association between hyperhomocysteinemia 
and the degree of carotid atherosclerosis in stroke patients.
Methods
We studied 97 Greek patients (51 males, 46 females) in our stroke unit who were 
hospitalized as a result of ischemic stroke from March 2006 to May 2007. The mean 
age of the patients was 72.8 years. The patients were divided in two groups. The ﬁ  rst 
included 52 stroke patients with serum levels of homocysteine below 15 µmol/L. Neuropsychiatric Disease and Treatment 2008:4(2) 478
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In the second group, which included 45 patients, serum 
homocysteine exceeded this value. In all cases, the diagnosis 
of ischemic stroke was conﬁ  rmed by computer tomography 
of the brain. Major exclusion criteria included renal failure, 
thyroid disease, pregnancy, hepatic failure, tumors, and drugs 
such as antiepileptics, ﬁ  brates, hormone replacement therapy, 
folate, vitB12, and vitB6 which are known to inﬂ  uence 
homocysteine levels (Dierkes and Westphal 2005).
Measurements of carotid intima-media thickness (cIMT) 
were performed in the far wall of both carotids at three points: 
a) the carotid bifurcation, b) the common carotid arteries, 
1 cm proximal to the dilatation of the carotid bulb, and c) the 
internal carotid arteries, 1cm away from the bifurcation.
The study was approved by the Ethics Committee of our 
hospital.
Results
The mean serum homocysteine concentration and the mean 
cIMT of the patients in our study were 17.4 µmol/L and 
1.013 mm, respectively. Table 1 sets out the main clinical 
and biochemical parameters for the two groups. The mean 
homocysteine concentration was 11.5 µmol/L in the ﬁ  rst 
group and 21.5 µmol/L in the second group. The difference 
in cIMT between the two groups was not signiﬁ  cant. More 
speciﬁ  cally, cIMT in the ﬁ  rst group was 1.012 mm, and 
1.015 mm in the second group.
In contrast, the levels of serum folate concentration in the 
two groups differed signiﬁ  cantly (p  0.001). As expected, 
the level was higher in the ﬁ  rst group (21.3 nmol/L), but 
signiﬁ  cantly lower in the second group (16.7 nmol/L).
Moreover, the levels of vitB12 were also statistically 
different between the two groups (p  0.001). The mean value 
of vitB12 was 401 pmol/L in the ﬁ  rst group and 340 pmol/L 
in the second group.
Discussion
Our results indicate that serum levels of homocysteine do not 
correlate with cIMT in ischemic stroke patients. Therefore 
compared with those with low levels of homocysteine, the 
hyperhomocysteinemic stroke patients of our study presented 
with similar degree of atherosclerosis, as indicated by cIMT, 
which is considered to be a reliable marker of the atheroscle-
rotic process (Aminbakhsh and Mancini 1999).
A second conclusion was the reciprocal relationship 
between homocysteine and B vitamins, namely folate and 
vitamin B12. Both folate and vitamin B12 levels were raised 
in the ﬁ  rst group, but were signiﬁ  cantly lower in the second 
group. This result was not surprising, because both folate 
and vitamin B12 play an important role in the metabolism 
of homocysteine to methionine and cysteine, respectively 
(Finkelstein 2000). Our results conﬁ  rm previous studies that 
reached the same conclusion (Boushey et al 1994; Vermeulen 
et al 2000; Till et al 2005; Marcucci et al 2005).
There is still no consensus on whether homocysteine is 
a causative risk factor for cardiovascular events like stroke 
and coronary disease. Numerous epidemiological studies 
have correlated hyperhomocysteinemia to cardiovascular 
morbidity and mortality. A meta-analysis indicated that 
when homocysteine increases by 5 µmol/L, the relative 
cardiovascular risk increases by a factor of 1.6 and 1.8 in men 
and women, respectively (Brattstrom et al 1990; Boushey 
et al 1994). The same study estimated that 10% of the total 
cardiovascular risk could be attributed to hyperhomocyste-
inemia. In the Atherosclerosis Risk in Communities (ARIC) 
study, hyperhomocysteinemia was correlated with increased 
coronary atherosclerosis (Chambless et al 2002). The Perth 
Carotid Ultrasound Disease Assessment Study (CUDAS) 
associated homocysteine levels with carotid intima media 
thickness in 1111 asymptomatic patients (McQuillan et al 
1999). After adjustment for age, sex, and other conventional 
risk factors, subjects in the highest versus the lowest quartile 
of homocysteine had an odds ratio of 2.60 for increased 
IMT and 1.76 for carotid artery plaque. The authors of 
this study proposed that mild hyperhomocysteinemia is an 
independent risk factor for increased carotid artery wall 
thickness and plaque formation in the general population. 
However, other recent studies failed to conﬁ  rm this result. 
More speciﬁ  cally, Durga and colleagues (2004) found no 
Table 1 Mean values of main clinical and biochemical parameters 
in the two groups
 Group  I  (n  = 52)  Group II (n = 47)
Age (years)  72.6  72.9
BMI (kg/m2) 28.4 28.1
SBP (mmHg)  161  166
DBP (mmHg)  89  92
Homocysteine (µmol/l) 11.5  21.5*
Folate (nmol/l)  21.3  16.7*
VitB12 (pmol/l)  401  340*
Total Cholesterol (mg/dl)  157  160
LDL (mg/dl)  114  116
HDL (mg/dl)  50  47
Triglycerides (mg/dl)  152  148
Serum Creatinine (mg/dl)  0.91  0.94
cIMT (mm)  1.012  1.015
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; cIMT, carotid intima-media thickness.
Notes: *statistically signiﬁ  cant difference (p  0.001).Neuropsychiatric Disease and Treatment 2008:4(2) 479
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correlation between homocysteine and IMT in the general 
population in Netherlands. Voutilainen and colleagues (1998) 
found a positive association between homocysteine and cIMT 
only in men, but not in women.
Folic acid and vitamin B12 are important factors in the 
homocysteine metabolism. Boushey and colleagues (1994) 
showed that administration of folate, vitamin B6, or vitamin 
B12 decreased homocysteine levels by 42%, 5%, and 15%, 
respectively within 6 weeks. In 1998, the United States Food 
and Drug Administration (FDA) required all cereal-grain 
products to be fortiﬁ  ed with folic acid (Grosse et al 2005). 
The intention was that the typical daily ingestion of folate 
would increase by approximately 100 µg.
To summarize, our study failed to conﬁ  rm the associa-
tion of hyperhomocysteinemia with cIMT in ischemic stroke 
patients. Large, prospective, multicentre studies are needed 
to more thoroughly investigate the role of homocysteine in 
the atherosclerotic process.
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